Medtech giant Abbott Laboratories Inc. and UK-based Angle PLC announced today they will collaborate on a breast cancer liquid biopsy study evaluating Angle's Parsortix circulating tumor cells harvesting system to determine HER-2 status when combined with Abbott's PathVysion HER-2 DNA FISH probe.
Abbott's FDA-approved gene-therapy test helps physicians determine which patient may be the best candidate for Roche/Genentech's Herceptin (trastuzumab)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?